Navigation Links
Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford
Date:3/3/2008

Unrestricted Educational Grant Supports Diagnosis and Patient Access to

Care

STANFORD, Calif., March 3 /PRNewswire/ -- The Jeffrey Modell Foundation (JMF) and Talecris Biotherapeutics, Inc. have donated $150,000 to Lucile Packard Children's Hospital at Stanford to expand clinical care and outreach for children with primary immunodeficiency (PI), the two organizations announced today.

PI is a term that encompasses more than 150 diseases caused by an immune system that does not function properly. Stanford's program, one of 37 worldwide supported by the JMF, focuses on the diagnosis, care, and treatment of people suffering from PI.

"Early recognition and diagnosis of PI can save lives and improve health outcomes for children," said David B. Lewis, M.D., professor of pediatrics, immunology and transplantation biology. "The educational and diagnostic programs made possible through this support will improve care for patients with PI, and will also generate cutting edge research opportunities," said Lewis, who also is director of the Jeffrey Modell Center for Research and Comprehensive Care for Primary Immunodeficiencies at Stanford University School of Medicine and Lucile Packard Children's Hospital.

"We are thrilled to support this important work at Packard Children's Hospital, in collaboration with Talecris Biotherapeutics," said Fred Modell, co-founder of the JMF. "Experts estimate that as many as 500,000 cases of PI remain undiagnosed in the United States, and our goal is to give every child a chance to lead a healthy, normal life."

Vicki Modell, co-founder of the JMF, noted that "a large, undiagnosed population of children and young adults continues to suffer from these diseases, which keep them from enjoying a full life. For example, they often miss 30 or 40 days of school every year. Their illness interrupts their activities, detours their plans, and shatters their dreams."

PI affe
'/>"/>

SOURCE Talecris Biotherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Nastech Pharmaceutical Company Announces the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery
2. Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team
3. James Marsden and Ashley & Jeffrey McDermott to Receive Honors at the Tourette Syndrome Association 2008 Champion of Children Awards Dinner
4. National Patient Safety Foundation Partners with Vocera Communications
5. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
6. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
7. AIDS Healthcare Foundation Applauds City Commissioners Support of Diversity, Urges Call for Mayors Resignation
8. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
9. Judge Rules That Florida Disease Management Program Serving 8,000 HIV/AIDS Patients Should Be Re-bid, Says AIDS Healthcare Foundation
10. The Tug McGraw Foundation Announces 2007 Fundraising Gala
11. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...t. 6 /PRNewswire/ -- Developed in collaboration wi...ades, CA is introducing,Revolutionary Breast Surfa...c Surgery office of Dr. Steve Laverson this week i...he first of its kind, and is based on,breakthrough...with,innovative proprietary software. The XS-300(T...
(Date:10/6/2008)...ct. 6 /PRNewswire/ -- The organizers of Informex a...e on Global Sourcing for the,Pharmaceutical Indust...inceton Marriott in New Jersey USA., The conferen... the,Global Sourcing Council, and boasts an unpara...e likes of Johnson & Johnson, Bristol Myers Squibb...
(Date:10/6/2008)... LegalView recently posted detailed inform...he potentially serious side effects caused by the ... the drug,s potential side effects are the develop... for young adult and child patients. , ...- LegalView, the number one resource for everythin...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rece...Garden Valley, Texas October 6, 2008 -- www.seamob...l provider of communications services to remote lo...s to the FoxNews channel via satellite to Mercy Sh...ica Mercy. The Africa Mercy is the world,s larges...
Breaking Medicine News(10 mins):Health News:Plan Your Breasts in 3-D 2Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3
... is not widely prescribed by the physicians to tho...tients with abnormal heart rhythm. They are less c...ates among them are the highest. In case of elders..., atrial fibrillation, are not prescribed warfarin...
... reducing the bad cholesterol. For example food li...anadian researchers said that by combining these f...ople should go in for such diet as they are at a h... These diets reduce the bad cholesterol (LDL) as e...
... a common feature in the hill state of Himachal Pr...t every year on an average//, with the gender rati...cking factor is that despite such unchecked preval... convicted so far. The hill state of Himachal Pra...
...spread of HIV/AIDS, that has been haunting Papua N...cided to contribute $34 million//. PNG has the hig.... The health minister, Dr Puka Temu who is worki... Prime Minister has welcomed the initiative. He fu...
Other Medicine News:Health News:Warfarin the Not So Popular Drug for Stroke 2Health News:Choose Foods That Keep Bad Cholesterol at Bay 2Health News:Female Ratio Drops Alarmingly In Himachal Due To Feticides 2
(Date:10/6/2008)...ay Eliminate 6 Weeks of Radiation Therapy -, Event...nternet Wednesday, October 22, 2008, 3 - 4 p.m.... , HAMPTON, Va., Oct. 6 / Questions ...sed with breast cancer in May. Would she have the,...ation or chemotherapy?, , To view the Multimedia...
(Date:10/3/2008)... Jersey is the newest study site, PHILADELPHIA, O...spital,of Philadelphia today received a contract t...,s Study. Children,s Hospital will manage local,pa...rlington County, New,Jersey. The study is funded b...rs anticipate approximately 1,000 families in Burl...
(Date:10/2/2008)...the Results of Rosetta Genomics, microRNA-based,Te...amous From non Squamous non Small Cell Lung C...ed on the miRview(TM) Technology First Approved fo...gh Complexity Molecular Pathology Lab ... is Expecting to Launch miRview(TM) Squamous Later...
(Date:10/2/2008)...RNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASD...company focused on,endocrine therapy and oncology,...ge of patient recruitment for its Phase 2 trial in...ne-releasing hormone (LHRH) agonist,linked to doxo... patient,recruitment was taken following recent fi...
Breaking Medicine Technology:Photos: Sentara Joins 4 U.S. Hospitals in International 'TARGIT' Breast Cancer Trial 2The Children's Hospital of Philadelphia Announces New Regional Participant in The National Children's Study 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 4Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 5AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Evotec Expands Collaboration With InterMune 3744 1Evotec Expands Collaboration With InterMune 3744 2Evotec Expands Collaboration With InterMune 3744 3High levels of estrogen associated with breast cancer recurrence 2422 1High levels of estrogen associated with breast cancer recurrence 2422 2Secrets of cooperation between trees and fungi revealed 2419 1Secrets of cooperation between trees and fungi revealed 2419 2AHIP Statement on House Passage of Mental Health Parity Legislation 13613 1
...,s Oncology Group (COG) Study Presented at,America...HICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Im...used on developing monoclonal,antibodies to treat ... that treatment with epratuzumab plus standard,che...en with,B-precursor acute lymphoblastic leukemia (...
...t analyses of progression-free survival in,the SPA...ion in,relative risk of disease progression for pa...ded prior Taxotere use,geographies, as well as pr... /PRNewswire-FirstCall/ -- Pharmion,Corporation an...of,additional data from the double-blind, randomiz...
Other Medicine Technology:Promising Results with Epratuzumab and Chemotherapy in Children,with Acute Lymphoblastic Leukemia 2Promising Results with Epratuzumab and Chemotherapy in Children,with Acute Lymphoblastic Leukemia 3Promising Results with Epratuzumab and Chemotherapy in Children,with Acute Lymphoblastic Leukemia 4Promising Results with Epratuzumab and Chemotherapy in Children,with Acute Lymphoblastic Leukemia 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7
...ed for continuous, random access operation, the El...rge volume laboratories that want to maximize prod...mplicity, flexibility and Stat capabilities of the...e changing needs of an aggressive laboratory testi...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t
Sample throughput of up to 80 tests per hour (4 modules). Low maintenance requirements. Continuous random access. 25 - 100 channels on board. 1008 tests or 6 hours of walkaway operation.
The Embla 96/384 well washer is a top-loading, robotic-compatible plate washer for 96- and 384-well microplate washing. It is ideal for ELISAs and most cell applications.
Medicine Products: